Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Follow-up of cardiovascular risk markers in hypertensive patients treated with irbesartan: results of the i-SEARCH Plus Registry.

Tebbe U, Bramlage P, Lüders S, Cuneo A, Sistig P, de Haan F, Schmieder R, Böhm M, Paar WD, Schrader J.

J Clin Hypertens (Greenwich). 2010 Dec;12(12):909-16. doi: 10.1111/j.1751-7176.2010.00363.x. Epub 2010 Aug 20.

2.

[Long-term follow-up of cardiovascular risk markers in patients with hypertension. Rationale, design, and baseline characteristics of the i-Search Plus Registry].

Tebbe U, Lüders S, de Haan F, Bramlage P, Böhm M, Thoenes M, Paar WD, Schrader J; i-SEARCH Plus Registers.

Med Klin (Munich). 2007 Oct 15;102(10):824-32. German.

PMID:
17928966
3.

N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.

Olsen MH, Wachtell K, Nielsen OW, Hall C, Wergeland R, Ibsen H, Kjeldsen SE, Devereux RB, Dahlöf B, Hildebrandt PR.

J Hypertens. 2006 Aug;24(8):1531-9.

PMID:
16877955
4.

N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.

Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P.

JAMA. 2005 Apr 6;293(13):1609-16.

PMID:
15811980
5.

Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex.

Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR.

J Hypertens. 2008 Jan;26(1):26-34.

PMID:
18090537
6.

Risk stratification in stable coronary artery disease: superiority of N-terminal pro B-type natriuretic peptide over high-sensitivity C-reactive protein, gamma-glutamyl transferase, and traditional risk factors.

Bode E, Wuppinger T, Bode T, Alber H, Ulmer H, Pachinger O, Mair J.

Coron Artery Dis. 2012 Mar;23(2):91-7. doi: 10.1097/MCA.0b013e32834f1165.

PMID:
22157356
7.

Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease.

Huang PH, Lu TM, Wu TC, Lin FY, Chen YH, Chen JW, Lin SJ.

Coron Artery Dis. 2008 May;19(3):187-93. doi: 10.1097/MCA.0b013e3282f399e2.

PMID:
18418236
8.

Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study.

Lorgis L, Zeller M, Dentan G, Sicard P, Buffet P, L'Huillier I, Beer JC, Vincent-Martin M, Makki H, Gambert P, Cottin Y; RICO Survey Working Group.

BMJ. 2009 May 6;338:b1605. doi: 10.1136/bmj.b1605.

9.

Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease.

Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, Neal BC, Patel A, MacMahon SW.

Hypertension. 2005 Jan;45(1):69-74. Epub 2004 Nov 29.

10.

N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS.

Welsh P, Doolin O, Willeit P, Packard C, Macfarlane P, Cobbe S, Gudnason V, Di Angelantonio E, Ford I, Sattar N.

Eur Heart J. 2013 Feb;34(6):443-50. doi: 10.1093/eurheartj/ehs239. Epub 2012 Aug 31. Erratum in: Eur Heart J. 2013 Apr;34(15):1094.

11.

Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study.

Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA.

Am J Med. 2008 Jan;121(1):50-7. doi: 10.1016/j.amjmed.2007.06.030.

12.

Prognostic value of serum biomarkers in association with TIMI risk score for acute coronary syndromes.

Manenti ER, Bodanese LC, Camey SA, Polanczyk CA.

Clin Cardiol. 2006 Sep;29(9):405-10.

13.

Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.

Goei D, Hoeks SE, Boersma E, Winkel TA, Dunkelgrun M, Flu WJ, Schouten O, Bax JJ, Poldermans D.

Coron Artery Dis. 2009 May;20(3):219-24. doi: 10.1097/MCA.0b013e3283219e47.

PMID:
19322079
14.
15.

N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.

Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P.

J Hypertens. 2004 Aug;22(8):1597-604.

PMID:
15257184
16.

New risk markers may change the HeartScore risk classification significantly in one-fifth of the population.

Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR.

J Hum Hypertens. 2009 Feb;23(2):105-12. doi: 10.1038/jhh.2008.112. Epub 2008 Sep 11.

PMID:
18784734
17.

Microalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartan.

de Alvaro F, Velasco O, Honorato J, Calvo C, Parrondo I; KORAL HT Investigators.

Kidney Int Suppl. 2005 Jan;(93):S29-34.

PMID:
15613064
18.

The prognostic value of the plasma N-terminal pro-brain natriuretic peptide level on all-cause death and major cardiovascular events in a community-based population.

Zhu Q, Xiao W, Bai Y, Ye P, Luo L, Gao P, Wu H, Bai J.

Clin Interv Aging. 2016 Feb 16;11:245-53. doi: 10.2147/CIA.S98151. eCollection 2016.

20.

Supplemental Content

Support Center